AbbVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 14, 2020, reports on events occurring on May 13 and May 14, 2020. AbbVie Inc. completed previously announced exchange offers and consent solicitations to retire outstanding notes issued by Allergan entities (Allergan Finance, Allergan Inc., Allergan Sales, and Allergan Funding) and replace them with new notes issued directly by AbbVie.
Key Financial Metrics and Debt Restructuring
The filing details a significant debt restructuring involving the tender and acceptance of approximately $13.6 billion in USD Allergan Notes and approximately €4.1 billion in Euro Allergan Notes. In exchange, AbbVie issued new unsecured, unsubordinated senior notes with identical principal amounts, interest rates, and maturity dates.
| Note Series (USD) | Principal Tendered/Accepted | Outstanding After Settlement |
|---|---|---|
| 3.375% Senior Notes due 2020 | $311,602,000 | $338,398,000 |
| 4.875% Senior Notes due 2021 | $431,559,000 | $18,441,000 |
| 5.000% Senior Notes due 2021 | $1,175,701,000 | $24,299,000 |
| 3.450% Senior Notes due 2022 | $2,627,036,000 | $251,188,000 |
| 3.250% Senior Notes due 2022 | $1,462,358,000 | $237,642,000 |
| 2.800% Senior Notes due 2023 | $244,575,000 | $105,425,000 |
| 3.850% Senior Notes due 2024 | $945,394,000 | $91,346,000 |
| 3.800% Senior Notes due 2025 | $2,890,467,000 | $130,225,000 |
| 4.550% Senior Notes due 2035 | $1,681,354,000 | $107,646,000 |
| 4.625% Senior Notes due 2042 | $389,217,000 | $67,493,000 |
| 4.850% Senior Notes due 2044 | $1,008,583,000 | $70,777,000 |
| 4.750% Senior Notes due 2045 | $827,096,000 | $53,860,000 |
Euro-denominated notes were also exchanged, including Floating Rate Notes due 2020 (€547,703,000 tendered) and various fixed-rate senior notes totaling approximately €3.5 billion tendered. The filing does not provide specific revenue, profit, cash flow, or margin data for the period.
Material Changes and Covenant Amendments
Supplemental indentures were executed to eliminate substantially all covenants, restrictive provisions, events of default, and guarantees associated with the original Allergan Notes. These amendments became operative on the settlement date. The new notes issued by AbbVie rank equally with all existing and future unsecured, unsubordinated indebtedness.
Guidance, Risks, and Contingencies
AbbVie entered into a Registration Rights Agreement with dealer managers (including Morgan Stanley, BofA Securities, and Citigroup). AbbVie agreed to use commercially reasonable efforts to file a registration statement for a registered offer to exchange the new notes. If the exchange offer is not completed within 365 days of issuance, or if a shelf registration is not declared effective within specific timelines, AbbVie is obligated to pay additional interest on the notes. The filing does not contain forward-looking guidance on revenue or earnings.
Key Facts for Investor Verification
- Debt Assumption: AbbVie has assumed the liability for the tendered Allergan notes, consolidating debt under its own balance sheet.
- Covenant Removal: The restructuring successfully removed restrictive covenants and guarantees from the original Allergan indentures.
- Registration Rights: Verify the timeline for the required registration statement filing to avoid potential additional interest costs.
- Remaining Allergan Debt: A portion of the original Allergan notes was not tendered and remains outstanding under the original indentures (e.g., $338 million of the 2020 notes).
- Liquidity Impact: The filing does not disclose the immediate cash impact or liquidity position resulting from the exchange.